Bolstering CAR-T therapies by tackling CRS, with Teresa Whalen

Providing cures for cancers previously thought uncurable, CAR-T therapies have been a bright success story for cell therapy. But they’re not without their problems: in addition to expensive infrastructure challenges, CAR-T therapies also have to deal with side effects, the most common of which is cytokine release syndrome (CRS).

At LSX in Boston last month, editor-in-chief Jonah Comstock spoke with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for CRS and a related syndrome called Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).

In the video below, Whalen discusses her company’s promising drug candidate and how it could potentially improve the safety profile for a wide variety of CAR-T therapies without impeding their efficacy. She also shares some of her key takeaways from the LSX CEO Forum.